Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) reported Q2 2026 PEMGARDA® net product revenue of $14.3 million, up 21% from $11.8 million in Q2 2025, driven by higher patient demand. Ending cash and cash equivalents were $160.1 million, which the company anticipates will fund operations through the DECLARATION pivotal data readout and support potential commercial launch readiness for VYD2311.
The pivotal DECLARATION Phase 3 trial of VYD2311 completed enrollment and is approaching its planned analysis, with top-line data planned later in Q3 2026. The LIBERTY Phase 3 trial is fully dosed, with top-line data expected in late Q3 2026. Invivyd is also advancing additional monoclonal antibody candidates, including VMS063 for measles and VBY329 for RSV, toward IND readiness in 2H 2026.
Q2 2026 R&D expenses rose to $29.4 million from $9.6 million, SG&A to $29.5 million from $16.6 million, and net loss increased to $44.4 million from $14.7 million, with net loss per share of $0.14 versus $0.12 a year earlier.
Invivyd (Nasdaq: IVVD) reported that on August 1, 2026, it granted stock options to ten newly hired non-executive employees to purchase an aggregate of 277,500 common shares under the 2026 Inducement Plan, as material inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a per-share exercise price of $0.535, equal to the July 31, 2026 closing price of Invivyd’s stock. Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments, subject to continued service. The options have a 10-year term and remain subject to the plan’s terms.
Invivyd (Nasdaq: IVVD) received FDA notice that the Emergency Use Authorization (EUA) for PEMGARDA will terminate on June 29, 2027, following HHS’ planned end of the COVID-19 EUA declaration.
The company remains in dialogue with FDA on next regulatory steps and believes existing clinical and post-authorization data can support a future Biologics License Application for PEMGARDA, a monoclonal antibody used for COVID-19 pre-exposure prophylaxis in certain immune-compromised patients.
Invivyd (Nasdaq: IVVD) granted stock options as employment inducements under Nasdaq Listing Rule 5635(c)(4). On July 1, 2026, 14 newly hired non-executive employees received options for an aggregate 493,000 common shares at an exercise price of $0.8544 per share.
Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments, subject to continuous service. The options have a 10-year term and were issued under the 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) completed enrollment in its Phase 3 LIBERTY trial evaluating investigational COVID-19 antibody VYD2311 versus an mRNA COVID-19 vaccine in healthy adults. The randomized, double-blind study focuses on side effects and tolerability over seven days and also assesses safety and immune response when VYD2311 and vaccine are given together. Initial topline data are expected in Q3 2026 and may be reported with results from the pivotal DECLARATION trial, both within the broader REVOLUTION program supporting VYD2311 as a potential COVID-19 prevention option.
Invivyd (Nasdaq: IVVD) dosed first participants in LIBERTY, a Phase 3 trial in healthy adults evaluating the safety, tolerability, and immunology of COVID-19 prevention with VYD2311, mRNA vaccine, and their co-administration.
The trial, part of the broader REVOLUTION program with pivotal DECLARATION, plans ~210 participants and targets topline data in Q3 2026.
Invivyd (Nasdaq: IVVD) granted stock options as inducement awards to new employees. On June 1, 2026, 17 newly hired non-executive employees received options to purchase an aggregate of 513,500 shares under the 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4).
The options have a $1.22 per share exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting monthly, subject to continuous service.
Invivyd (Nasdaq: IVVD) has completed enrollment in the upsized Phase 3 DECLARATION trial of VYD2311, an investigational monoclonal antibody to prevent symptomatic COVID-19 in adults and adolescents. The BLA-enabling, randomized, placebo-controlled study tests single and monthly intramuscular dosing. Top-line results are expected in approximately late Q3 2026.
Invivyd (Nasdaq: IVVD) will join several June 2026 investor events, including the Jefferies Global Healthcare Conference in New York, the H.C. Wainwright “HCW @ Home” Series, and BTIG Infectious Disease Day 2026.
Fireside chats will be webcast and archived on Invivyd’s investor website.
Invivyd (Nasdaq: IVVD) reported Q1 2026 PEMGARDA net product revenue of $13.7 million, up 22% from Q1 2025. Cash and equivalents were $184.2 million plus ~$20 million raised via ATM in April. R&D and SG&A rose sharply, driving a $41.4 million net loss, while pivotal VYD2311 DECLARATION data are now expected in Q3 2026. The company advanced VYD2311 programs, received multiple FDA interactions, and expanded its pipeline with measles candidate VMS063 and RSV candidate VBY329.